Abstract
Objectives: The role of hereditary thrombophilia in reproductive failure (RF) is strongly debatable. In this retrospective single-center study, we analyzed pregnancy outcome in 175 women screened for thrombophilia after at least one event of RF. Results: The prevalence of thrombophilia in our cohort was 33.4%. Pregnancy survival curves were not different according to severity (log-rank, p = 0.302) or type of thrombophilia (log-rank, p = 0.532). In total, 81.7% of 175 subsequent pregnancies were proceeded with LMWH. Concomitant use of ASA was prescribed in 75 pregnancies according to physician choice. The primary endpoint was live birth rate (LBR) that succeeded in 152/175 next pregnancies (86.8%) and late obstetric complications (LOBC) which occurred in 17/175 next pregnancies (9.8%). In logistic regression analysis, neither the severity nor the type of thrombophilia was important for any pregnancy outcome (LBR or LOBC). Considering therapeutic interventions, the use of LMWH ± ASA was not related to LBR or LOBC. The only factor inversely related to LBR was age above the cutoff value of 35.5 years (p = 0.049). Conclusions: Incidence of thrombophilia is increased among women with RF, but the severity or type of thrombophilia is not related to pregnancy outcome.
References
1.
Youssef
A
, Lashley
L
, Dieben
S
, Verburg
H
, van der Hoorn
M-L
. Defining recurrent pregnancy loss: associated factors and prognosis in couples with two versus three or more pregnancy losses
. Reprod Biomed Online
. 2020
;41
(4
):679
–85
. 2.
Han
AR
, Han
JW
, Lee
SK
. Inherited thrombophilia and anticoagulant therapy for women with reproductive failure
. Am J Reprod Immunol
. 2021
;85
:e13378
. .3.
Kupferminc
MJ
, Eldor
A
, Steinman
N
, Many
A
, Bar-Am
A
, Jaffa
A
, Increased frequency of genetic thrombophilia in women with complications of pregnancy
. N Engl J Med
. 1999
;340
(1
):9
–13
. 4.
Nahas
R
, Saliba
W
, Elias
A
, Elias
M
. The prevalence of thrombophilia in women with recurrent fetal loss and outcome of anticoagulation therapy for the prevention of miscarriages
. Clin Appl Thromb Hemost
. 2018
;24
(1
):122
–8
. 5.
Dizon-Townson
DS
, Meline
L
, Nelson
LM
, Varner
M
, Ward
K
. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction
. Am J Obstet Gynecol
. 1997
;177
(2
):402
–5
. 6.
An
J
, Waitara
MS
, Bordas
M
, Arumugam
V
, Hoffmann
RG
, Petrich
BG
, Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model
. Blood
. 2013
;121
(11
):2127
–34
. 7.
Clark
P
, Walker
ID
, Langhorne
P
, Crichton
L
, Thomson
A
, Greaves
M
, SPIN (Scottish pregnancy intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage
. Blood
. 2010
;115
(21
):4162
–7
. 8.
de Vries
JI
, van Pampus
MG
, Hague
WM
, Bezemer
PD
, Joosten
JH
. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT
. J Thromb Haemost
. 2012
;10
(1
):64
–72
. .9.
Pasquier
E
, de Saint Martin
L
, Bohec
C
, Chauleur
C
, Bretelle
F
, Marhic
G
, Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial
. Blood
. 2015
;125
(14
):2200
–5
. 10.
Visser
J
, Ulander
V-M
, Helmerhorst
FM
, Lampinen
K
, Morin-Papunen
L
, Bloemenkamp
KWM
, Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial
. Thromb Haemost
. 2011
;105
(2
):295
–301
. 11.
Kaandorp
SP
, Goddijn
M
, van der Post
JAM
, Hutten
BA
, Verhoeve
HR
, Hamulyák
K
, Aspirin plus heparin or aspirin alone in women with recurrent miscarriage
. N Engl J Med
. 2010
;362
(17
):1586
–96
.12.
Davenport
WB
, Kutteh
WH
. Inherited thrombophilias and adverse pregnancy outcomes: a review of screening patterns and recommendations
. Obstet Gynecol Clin North Am
. 2014
;41
(1
):133
–44
. .13.
Kutteh
WH
. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
. Am J Obstet Gynecol
. 1996
;174
(5
):1584
–9
. .14.
Robertson
L
, Wu
O
, Langhorne
P
, Twaddle
S
, Clark
P
, Lowe
GDO
, Thrombophilia in pregnancy: a systematic review
. Br J Haematol
. 2006
;132
(2
):171
–96
. 15.
Hamedi
B
, Feulefack
J
, Khan
A
, Sergi
C
. Association between factor V Leiden mutation and recurrent pregnancy loss in the middle east countries: a Newcastle-Ottawa meta-analysis
. Arch Gynecol Obstet
. 2020
;302
(2
):345
–54
. 16.
Bashiri
A
, Giliutin
M
, Ziedenberg
H
, Plakht
Y
, Baumfeld
Y
. A proposed prognostic prediction tool for a live birth among women with recurrent pregnancy loss
. J Matern Fetal Neonatal Med
. Epub 2020 Nov 1
–. 17.
Marquard
K
, Westphal
LM
, Milki
AA
, Lathi
RB
. Etiology of recurrent pregnancy loss in women over the age of 35 years
. Fertil Steril
. 2010
;94
(4
):1473
–7
. 18.
Zheng
CJ
, Guo
SW
, Byers
B
. Modeling the maternal-age dependency of reproductive failure and genetic fitness
. Evol Dev
. 2000
;2
(4
):203
–7
. .19.
Karadağ
C
, Akar
B
, Gönenç
G
, Aslancan
R
, Yılmaz
N
, Çalışkan
E
. Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation
. J Matern Fetal Neonatal Med
. 2020
;33
(11
):1934
–9
.20.
Intzes
S
, Symeonidou
M
, Zagoridis
K
, Stamou
M
, Spanoudaki
A
, Spanoudakis
E
. Hold your needles in women with recurrent pregnancy losses with or without hereditary thrombophilia: meta-analysis and review of the literature
. J Gynecol Obstet Hum Reprod
. 2021
;50
:101935
. 21.
Yagmur
E
, Bast
E
, Mühlfeld
AS
, Koch
A
, Weiskirchen
R
, Tacke
F
, High prevalence of sticky platelet syndrome in patients with infertility and pregnancy loss
. J Clin Med
. 2019
;8
(9
):1328
. 22.
Ruiz-Arguelles
GJ
, Garcés-Eisele
J
, Camacho-Alarcón
C
, Reyes-Nuñez
V
, Moncada-González
B
, Valdés-Tapia
P
, Primary thrombophilia in Mexico IX: the glycoprotein IIIa PLA1/A2 polymorphism is not associated with the sticky platelet syndrome phenotype
. Clin Appl Thromb Hemost
. 2013
;19
(6
):689
–92
. © 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
